Skip to content

Investigating the effects and neural mechanisms of oxytocin intervention in highly anxious individuals at different frequencies.

Investigating the effects and neural mechanisms of oxytocin intervention in highly anxious individuals at different frequencies.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121982
Enrollment
Unknown
Registered
2026-04-08
Start date
2026-04-08
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

People with high levels of anxiety.

Interventions

Nasal spray of oxytocin group (high-frequency intake):Take 24IU of oxytocin by nasal spray every day for five consecutive days
Nasal spray of oxytocin group (low-frequency intake):During the 5-day nasal spray intake, 24IU of oxytocin was administered on the first, third and fifth days, while a placebo (normal saline) was take
Placebo group:Nasal spray of normal saline (21IU) for five consecutive days

Sponsors

Institute of Brain and Psychological Science, Sichuan Normal University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 30 Years

Inclusion criteria

Inclusion criteria: To be eligible for inclusion, participants must meet the following criteria: (1) Female individuals aged 18 to 30 years. (2) Have trait anxiety scores above 45 on the State-Trait Anxiety Inventory (STAI). (3) Demonstrate comprehension of the study's purpose and willingly sign the informed consent form. (4) Be able to cooperate in completing the study procedures, including behavioral assessments, questionnaire measures, and brain imaging scans.

Exclusion criteria

Exclusion criteria: (1) Individuals with a history of bipolar disorder, schizophrenia, substance abuse, or other severe mental disorders; (2) Those at a high risk of suicide; (3) Individuals with neurological disorders such as epilepsy, traumatic brain injury, or Parkinson's disease. (4) Presence of severe cardiovascular diseases, significant liver or kidney dysfunction, thyroid disorders, or other physical conditions that may impact the safety of the study or the interpretation of results; (5) Women who are pregnant or breastfeeding; (6) Use of antidepressants, anti-anxiety medications, steroids, or nasal spray medications within the past 4 weeks. (7) Have participated in other clinical trials in the past 3 months; (8) Other circumstances where the researcher deems unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
State trait anxiety score;

Secondary

MeasureTime frame
Emotional picture behavior assessment score;Resting-state brain imaging network indicators;Task-state brain imaging index;

Countries

China

Contacts

Public ContactJuan Kou

Institute of Brain and Psychological Science, Sichuan Normal University

koujuan2012@foxmail.com+86 187 8223 8905

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026